Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer

被引:15
|
作者
Minami, Seigo [1 ,2 ]
Ihara, Shouichi [1 ]
Komuta, Kiyoshi [2 ]
机构
[1] Osaka Police Hosp, Dept Resp Med, Tenn Ku, 10-31 Kitayama Cho, Osaka, Osaka 5430035, Japan
[2] Daini Osaka Police Hosp, Dept Resp Med, Tenn Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan
关键词
Gustave Roussy immune score; Royal Marsden Hospital prognostic score; Extensive disease; Small cell lung cancer; Neutrophil-to-lymphocyte ratio; Number of metastatic sites; Lactate dehydrogenase; Serum albumin; TO-LYMPHOCYTE RATIO; PHASE-I; PROSPECTIVE VALIDATION; LACTATE-DEHYDROGENASE;
D O I
10.14740/wjon1275
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy inunune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMII score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC). Methods: We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times. Results: Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMI1 score (FIR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS. Conclusions: Both RMH score and GRIm-score are useful as inde- pendent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 50 条
  • [21] The prognostic value of the Naples prognostic score for patients with non-small-cell lung cancer
    Peng, Si-Min
    Ren, Jin-Jin
    Yu, Na
    Xu, Jia-Ying
    Chen, Guo-Chong
    Li, Xiaodong
    Li, Da-Peng
    Yang, Jing
    Li, Zeng-Ning
    Zhang, Yu-Song
    Qin, Li-Qiang
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
    Hatanaka, Takeshi
    Naganuma, Atsushi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Shimada, Noritomo
    Kawata, Kazuhito
    Kosaka, Hisashi
    Kakizaki, Satoru
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    Kumada, Takashi
    CANCER MEDICINE, 2023, 12 (04): : 4259 - 4269
  • [23] The Glasgow Prognostic Score Predicts Survival Outcomes in Patientswith Extensive-Stage Small Cell Lung Cancer
    Igawa, Satoshi
    Yamamoto, Hiroki
    Yamada, Kaori
    Akazawa, Yuki
    Manaka, Hiroya
    Yagami, Yuri
    Nakahara, Yoshiro
    Sato, Takashi
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    ONCOLOGY, 2023, 101 (11) : 695 - 704
  • [24] Improving patient selection and outcomes in phase I trials: validating the Royal Marsden Hospital prognostic score
    Drew, Y.
    Haney, S.
    Graham, J.
    Pilkington, M.
    Chapman, F.
    Hoben, J.
    Charlton, J.
    Plummer, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S182 - S183
  • [25] Prognostic Immune Markers in Non-Small Cell Lung Cancer
    Suzuki, Kei
    Kachala, Stefan S.
    Kadota, Kyuichi
    Shen, Ronglai
    Mo, Qianxing
    Beer, David G.
    Rusch, Valerie W.
    Travis, William D.
    Adusumilli, Prasad S.
    CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5247 - 5256
  • [26] Gustave Roussy Immune Score (GRIm-Score) Predicts Prognosis in Non-Small Cell Lung Cancer Patients Undergoing Nivolumab: A Multicenter Retrospective Study from Turkiye
    Majidova, Nargiz
    Yildirim, Sedat
    Kocaaslan, Erkam
    Guren, Ali Kaan
    Yildiz, Hacer Sahika
    Kircali, Muhammed Fatih
    Seyyar, Mustafa
    Sever, Nadiye
    Turan, Nedim
    Bayoglu, Ibrahim Vedat
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (04): : 206 - 212
  • [27] Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer
    Yotsukura, Masaya
    Ohtsuka, Takashi
    Kaseda, Kaoru
    Kamiyama, Ikuo
    Hayashi, Yuichiro
    Asamura, Hisao
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1311 - 1318
  • [28] Prognostic Markers in Small Cell Lung Cancer
    Nickolich, Myles
    Dowlati, Afshin
    CURRENT CANCER THERAPY REVIEWS, 2014, 10 (01) : 39 - 46
  • [29] A Prognostic Model Integrating Immunohistochemistry Markers for Extensive-Disease Small-Cell Lung Cancer
    Fu, R.
    Zhang, C.
    Zhang, J.
    Yang, J.
    Zhou, Q.
    Yang, X.
    Wu, Y.
    Zhong, W.
    Huang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S794 - S795
  • [30] Immune checkpoint expression score is an independent prognostic biomarker in resectable non-small cell lung cancer
    Uso, Marta
    Jantus-Lewintre, Eloisa
    Sirera, Rafael
    Calabuig, Silvia
    Pastor, Enrique
    Forteza, Jeronimo
    Camps, Carlos
    CANCER RESEARCH, 2015, 75